Gangliosides for acute spinal cord injury
The evidence available does not support the use of ganglioside treatment to reduce the death rate in spinal cord injury (SCI) patients. No evidence has yet emerged that ganglioside treatment improves recovery or quality of life in survivors.
SCI results in loss of feeling and movement. Care for people with SCI has improved, leading to an increase in survival rates. Attempts to improve patients’ feeling and movement have involved the use of a wide range of treatments. Laboratory studies have suggested that gangliosides may have protective effects on nerves and even help them to re-grow. Clinical trials have taken place using gangliosides (usually GM1 ganglioside) for a number of neurological conditions. The aim of this review is to quantify the evidence for the effectiveness and safety of gangliosides when used to treat acute SCI.
If you have found this summary helpful, please consider making a donation. If everyone who looked at our COVID-19 resources gave us just £2 per month, it would fund Evidence Aid’s life-saving work.